Recent evidence indicates that inflammation may significantly contribute to the pathogenesis of Alzheimer's disease (AD). Since the apo A-I mimetic peptide D-4F has been shown to inhibit atherosclerotic lesion formation and regress already existing lesions (in the presence of pravastatin) and the peptide also decreases brain arteriole inflammation, we undertook a study to evaluate the efficacy of oral D-4F coadministered with pravastatin on cognitive function and amyloid β (Aβ) burden in the hippocampus of APPSwe-PS1ΔE9 mice. Three groups of male mice were administered D-4F and pravastatin, Scrambled D-4F (ScD-4F, a control peptide) and pravastatin in drinking water, while drinking water alone served as control. The escape latency in the Morris Water Maze test was significantly shorter for the D-4F + statin administered animals compared to the other two groups. While the hippocampal region of the brain was covered with 4.2 ± 0.5 and 3.8 ± 0.6% of Aβ load in the control and ScD-4F + statin administered groups, in the D-4F + statin administered group Aβ load was only 1.6 ± 0.1%. Furthermore, there was a significant decrease in the number of activated microglia (p b 0.05 vs the other two groups) and activated astrocytes (p b 0.05 vs control) upon oral D-4F + statin treatment. Inflammatory markers TNFα and IL-1β levels were decreased significantly in the D-4F + statin group compared to the other two groups (for IL-1β p b 0.01 vs the other two groups and for TNF-α p b 0.001 vs control) and the expression of MCP-1 were also less in D-4F + statin administered group compared to the other two groups. These results suggest that the apo A-I mimetic peptide inhibits amyloid β deposition and improves cognitive function via exerting antiinflammatory properties in the brain.
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Alzheimer's disease (AD) is the world's leading cause of dementia and affects 12 million people worldwide. AD is a neurodegenerative disorder and is characterized by progressive cognitive impairment (Hebert et al., 2003) . Epidemiological and clinical studies suggest that inflammation and oxidative stress are implicated in AD (Akiyama et al., 2000; McGeer and McGeer, 2003; Christen, 2000; Pratico and Delanty, 2000) . However, the role of inflammation in the pathogenesis of AD is not clearly understood. Activated microglia release a variety of pro-inflammatory molecules which result in the exacerbation of the disease process and contribute to neuronal death (Yates et al, 2000) . On the other hand, activated microglia can possibly take up and degrade amyloid β (Aβ) (Boche and Nicoll, 2008) . Mouse models of AD also suggest that AD may have an inflammatory component contributing to the pathogenesis of this disease (Heneka et al., 2005; Kunjathoor et al., 2004) . Anti-inflammatory agents have been used as a therapy for AD (In t' Veld et al., 2001; Zandi et al., 2002) .
Hypercholesterolemia is also an important risk factor in the development of AD. Emerging evidence suggests that high dietary cholesterol increases Aβ accumulation and accelerates AD-related pathology (Li et al., 2003; Refolo et al., 2000) . High density lipoproteins (HDL) and apolipoprotein A-I (apo A-I), the major protein component of HDL, possess several important protective functions including facilitating reverse cholesterol transport (Barter and Rye, 2006) and thereby is inversely correlated to the development of atherosclerosis. Apo A-I has also been shown to possess anti-oxidant and anti-inflammatory properties (Navab et al., 2005a; Barter and Rye, 2006) . Apo A-I mimetic peptides were developed based on the presence of lipid-associating amphipathic α-helical domains in apo A-I (Segrest et al., 1992 , Anantharamaiah et al., 2007 . It has been shown that oral administration of D-4F, an apo A-I mimetic peptide synthesized from D-amino acids, remains intact in the circulation,
